Truist Financial analyst Joon Lee maintains $Verona Pharma (VRNA.US)$ with a buy rating, and sets the target price at $57.
According to TipRanks data, the analyst has a success rate of 49.7% and a total average return of 23.8% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Verona Pharma (VRNA.US)$'s main analysts recently are as follows:
Preliminary Q4 sales of $36M indicates that Ohtuvayre is consistently performing well above expectations in its initial quarters. The forecasts for both near-term trajectory and long-term peak sales have been revised upwards, reflecting an optimistic assessment of future financial performance.
Verona Pharma's fourth quarter pre-announcement was described as 'impressive', reflecting an optimistic revenue outlook for Ohtuvayre. Analysts highlight the relative ease of getting patients on Medicare Part B drugs compared to those on Medicare Part D. Additionally, pivotal data indicating that 150 physicians now prescribe Ohtuvayre to over 20 of their patients was noted. This trend is expected to grow as more physicians opt to prescribe this medication during scheduled visits for patients experiencing uncontrolled COPD symptoms.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.